Antiarrhythmic effects of verapamil.
D000284:Administration, Oral; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000503:physiopathology; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000628:therapy; D001282:Atrial Flutter / Q000188:drug therapy; D001283:Atrioventricular Node / Q000502:physiology; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use; D004554:Electric Countershock; D004594:Electrophysiology; D006439:Hemodynamics; D006801:Humans; D007700:Kinetics; D012849:Sinoatrial Node / Q000187:drug effects / Q000502:physiology; D013610:Tachycardia / Q000188:drug therapy; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy / Q000503:physiopathology; D014655:Vascular Resistance / Q000187:drug effects; D014700:Verapamil / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*
D000889:Anti-Arrhythmia Agents; D002121:Calcium Channel Blockers; D014700:Verapamil